These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 3003561)

  • 1. Study of species specificity in growth hormone-releasing factor (GRF) interaction with vasoactive intestinal peptide (VIP) receptors using GRF and intestinal VIP receptors from rat and human: evidence that Ac-Tyr1hGRF is a competitive VIP antagonist in the rat.
    Laburthe M; Couvineau A; Rouyer-Fessard C
    Mol Pharmacol; 1986 Jan; 29(1):23-7. PubMed ID: 3003561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist.
    Waelbroeck M; Robberecht P; Coy DH; Camus JC; De Neef P; Christophe J
    Endocrinology; 1985 Jun; 116(6):2643-9. PubMed ID: 2859987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural requirements for the activation of rat anterior pituitary adenylate cyclase by growth hormone-releasing factor (GRF): discovery of (N-Ac-Tyr1, D-Arg2)-GRF(1-29)-NH2 as a GRF antagonist on membranes.
    Robberecht P; Coy DH; Waelbroeck M; Heiman ML; de Neef P; Camus JC; Christophe J
    Endocrinology; 1985 Nov; 117(5):1759-64. PubMed ID: 2994998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor-mediated actions of growth hormone releasing factor on granulosa cell differentiation.
    Moretti C; Bagnato A; Solan N; Frajese G; Catt KJ
    Endocrinology; 1990 Nov; 127(5):2117-26. PubMed ID: 2171907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative structural requirements of thirty GRF analogs for interaction with GRF- and VIP receptors and coupling to adenylate cyclase in rat adenopituitary, liver and pancreas.
    Robberecht P; Waelbroeck M; Coy D; De Neef P; Camus JC; Christophe J
    Peptides; 1986; 7 Suppl 1():53-9. PubMed ID: 3018703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasoactive intestinal peptide receptor antagonists in rat seminal vesicle membranes.
    Rodríguez-Pena MS; Guijarro LG; Prieto JC
    Eur J Pharmacol; 1991 Nov; 208(3):207-12. PubMed ID: 1663044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ac-Tyr1hGRF discriminates between VIP receptors from rat liver and intestinal epithelium.
    Rouyer-Fessard C; Couvineau A; Voisin T; Laburthe M
    Life Sci; 1989; 45(9):829-33. PubMed ID: 2549322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ac His1 [D-Phe2, K15, R16, L27] VIP (3-7)/GRF (8-27)--a VPAC1 receptor antagonist--is an inverse agonist on two constitutively active truncated VPAC1 receptors.
    Vertongen P; Langlet C; Langer I; Gaspard N; Robberecht P
    Peptides; 2004 Nov; 25(11):1943-9. PubMed ID: 15501526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
    Zawilska JB; Niewiadomski P; Nowak JZ
    Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selectivity for binding of peptide analogs to vascular receptors for vasoactive intestinal peptide.
    Rorstad OP; Wanke I; Coy DH; Fournier A; Huang M
    Mol Pharmacol; 1990 Jun; 37(6):971-7. PubMed ID: 2163020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of GRF with VIP receptors and stimulation of adenylate cyclase in rat and human intestinal epithelial membranes. Comparison with PHI and secretin.
    Laburthe M; Amiranoff B; Boige N; Rouyer-Fessard C; Tatemoto K; Moroder L
    FEBS Lett; 1983 Aug; 159(1-2):89-92. PubMed ID: 6307754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasoactive intestinal peptide and intraocular pressure: adenylate cyclase activation and binding sites for vasoactive intestinal peptide in membranes of ocular ciliary processes.
    Mittag TW; Tormay A; Podos SM
    J Pharmacol Exp Ther; 1987 Apr; 241(1):230-5. PubMed ID: 3033201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GRF is a highly potent activator of adenylate cyclase in the normal human, bovine and rat pituitary: interaction with somatostatin.
    Reyl-Desmars F; Baird A; Zeytin FN
    Biochem Biophys Res Commun; 1985 Mar; 127(3):977-85. PubMed ID: 2859017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The entire vasoactive intestinal polypeptide molecule is required for the activation of the vasoactive intestinal polypeptide receptor: functional and binding studies on opossum internal anal sphincter smooth muscle.
    Chakder S; Rattan S
    J Pharmacol Exp Ther; 1993 Jul; 266(1):392-9. PubMed ID: 8392560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rat hypothalamic GRF elicits its biologic action in GH3 cells by interaction with VIP- preferring receptor site(s).
    Zeytin FN; Reyl-Desmars F; Rathbun T
    Biochem Biophys Res Commun; 1985 Mar; 127(3):992-8. PubMed ID: 2985067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adrenocorticotropin, vasoactive intestinal polypeptide, growth hormone-releasing factor, and dynorphin compete for common receptors in brain and adrenal.
    Li ZG; Queen G; LaBella FS
    Endocrinology; 1990 Mar; 126(3):1327-33. PubMed ID: 1968378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in the goose cerebral cortex.
    Zawilska JB; Niewiadomski P; Nowak JZ
    Pol J Pharmacol; 2004; 56(2):203-11. PubMed ID: 15156071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of VIP receptor-effector system antagonists in rat and mouse peritoneal macrophages.
    Pozo D; Montilla ML; Guerrero JM; Calvo JR
    Eur J Pharmacol; 1997 Mar; 321(3):379-86. PubMed ID: 9085051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.
    Sotomayor S; Carmena MJ; Schally AV; Varga JL; Sánchez-Chapado M; Prieto JC; Bajo AM
    Int J Oncol; 2007 Nov; 31(5):1223-30. PubMed ID: 17912451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of vasoactive intestinal peptide (VIP) and N-terminally modified VIP analogs with rat pancreatic, hepatic and pituitary membranes.
    Robberecht P; Coy DH; De Neef P; Camus JC; Cauvin A; Waelbroeck M; Christophe J
    Eur J Biochem; 1986 Aug; 159(1):45-9. PubMed ID: 3017717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.